Papp K - Search Results

1

Relapse, rebound, and psoriasis adverse events: an advisory group report.

Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Carey W, et al. Among authors: papp k. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S171-81. doi: 10.1016/j.jaad.2005.10.029. J Am Acad Dermatol. 2006. PMID: 16488339 Review.

2

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group. Gordon KB, et al. Among authors: papp ka. JAMA. 2003 Dec 17;290(23):3073-80. doi: 10.1001/jama.290.23.3073. JAMA. 2003. PMID: 14679270 Clinical Trial.

3

Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.

Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Menter A, et al. J Drugs Dermatol. 2004 Jan-Feb;3(1):27-38. J Drugs Dermatol. 2004. PMID: 14964744 Clinical Trial.

4

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

5

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Tyring S, et al. Among authors: papp k. Lancet. 2006 Jan 7;367(9504):29-35. doi: 10.1016/S0140-6736(05)67763-X. Lancet. 2006. PMID: 16399150 Clinical Trial.

6

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

Bissonnette R, Papp K, Poulin Y, Lauzon G, Aspeslet L, Huizinga R, Mayo P, Foster RT, Yatscoff RW, Maksymowych WP; ISA247 Psoriasis Study Group. Bissonnette R, et al. Among authors: papp k. J Am Acad Dermatol. 2006 Mar;54(3):472-8. doi: 10.1016/j.jaad.2005.10.061. Epub 2006 Jan 23. J Am Acad Dermatol. 2006. PMID: 16488299 Clinical Trial.

7

Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.

Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL; Efalizumab Study Group. Papp KA, et al. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S164-70. doi: 10.1016/j.jaad.2005.10.032. J Am Acad Dermatol. 2006. PMID: 16488338 Clinical Trial.

8

Long-term management of plaque psoriasis with continuous efalizumab therapy.

Menter A, Leonardi CL, Sterry W, Bos JD, Papp KA. Menter A, et al. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S182-8. doi: 10.1016/j.jaad.2005.10.028. J Am Acad Dermatol. 2006. PMID: 16488340 Review. No abstract available.

9

A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence.

Poulin Y, Papp KA, Carey W, Gulliver W, Gupta AK. Poulin Y, et al. Among authors: papp ka. J Cutan Med Surg. 2006;9 Suppl 1:10-7. doi: 10.1007/s10227-006-0102-2. J Cutan Med Surg. 2006. PMID: 16633861 Review.

10

Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II.

Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Papp KA, et al. J Cutan Med Surg. 2005 Dec;9(6):313-23. doi: 10.1007/s10227-005-0117-0. J Cutan Med Surg. 2005. PMID: 16699903 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

709 results

Search Page